SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants
Release Date:
In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery. Subscribe to Eagle’s Eye View
SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants